转移性尿路上皮癌的抗体-药物结合物：通往天堂的高速公路。

IF 3.2 Q3 ONCOLOGY

World journal of clinical oncology Pub Date : 2025-09-24 DOI:10.5306/wjco.v16.i9.106646

Alberto D'Angelo, Martina Catalano, Irene De Gennaro Aquino, Valeria Gangi, Giandomenico Roviello

{"title":"转移性尿路上皮癌的抗体-药物结合物：通往天堂的高速公路。","authors":"Alberto D'Angelo, Martina Catalano, Irene De Gennaro Aquino, Valeria Gangi, Giandomenico Roviello","doi":"10.5306/wjco.v16.i9.106646","DOIUrl":null,"url":null,"abstract":"Metastatic urothelial carcinoma (mUC) is a challenging malignancy with historically limited treatment options. Advances in understanding its biology have enabled the development of innovative therapies, including immune checkpoint inhibitors and antibody-drug conjugates (ADCs). ADCs, such as enfortumab vedotin, sacituzumab govitecan, and trastuzumab deruxtecan, represent transformative advancements, offering targeted delivery of cytotoxic agents. This review highlights the evolving role of ADCs in mUC, examining their mechanisms, clinical efficacy, patient selection criteria, genetic insights, and future directions in personalized treatment strategies.","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 9","pages":"106646"},"PeriodicalIF":3.2000,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12476608/pdf/","citationCount":"0","resultStr":"{\"title\":\"Antibody-drug conjugates in metastatic urothelial cancer: Highway to heaven.\",\"authors\":\"Alberto D'Angelo, Martina Catalano, Irene De Gennaro Aquino, Valeria Gangi, Giandomenico Roviello\",\"doi\":\"10.5306/wjco.v16.i9.106646\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Metastatic urothelial carcinoma (mUC) is a challenging malignancy with historically limited treatment options. Advances in understanding its biology have enabled the development of innovative therapies, including immune checkpoint inhibitors and antibody-drug conjugates (ADCs). ADCs, such as enfortumab vedotin, sacituzumab govitecan, and trastuzumab deruxtecan, represent transformative advancements, offering targeted delivery of cytotoxic agents. This review highlights the evolving role of ADCs in mUC, examining their mechanisms, clinical efficacy, patient selection criteria, genetic insights, and future directions in personalized treatment strategies.\",\"PeriodicalId\":23802,\"journal\":{\"name\":\"World journal of clinical oncology\",\"volume\":\"16 9\",\"pages\":\"106646\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2025-09-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12476608/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"World journal of clinical oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5306/wjco.v16.i9.106646\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5306/wjco.v16.i9.106646","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

转移性尿路上皮癌（mUC）是一种具有挑战性的恶性肿瘤，历史上治疗方案有限。对其生物学的理解的进步使创新疗法的发展成为可能，包括免疫检查点抑制剂和抗体-药物偶联物（adc）。adc，如enfortumab vedotin、sacituzumab govitecan和曲妥珠单抗deruxtecan，代表了变革性的进步，提供了细胞毒性药物的靶向递送。这篇综述强调了adc在mUC中不断发展的作用，研究了它们的机制、临床疗效、患者选择标准、遗传学见解以及个性化治疗策略的未来方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Antibody-drug conjugates in metastatic urothelial cancer: Highway to heaven.

Metastatic urothelial carcinoma (mUC) is a challenging malignancy with historically limited treatment options. Advances in understanding its biology have enabled the development of innovative therapies, including immune checkpoint inhibitors and antibody-drug conjugates (ADCs). ADCs, such as enfortumab vedotin, sacituzumab govitecan, and trastuzumab deruxtecan, represent transformative advancements, offering targeted delivery of cytotoxic agents. This review highlights the evolving role of ADCs in mUC, examining their mechanisms, clinical efficacy, patient selection criteria, genetic insights, and future directions in personalized treatment strategies.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

World journal of clinical oncology ONCOLOGY-

自引率

0.00%

发文量

585

期刊介绍： The WJCO is a high-quality, peer reviewed, open-access journal. The primary task of WJCO is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of oncology. In order to promote productive academic communication, the peer review process for the WJCO is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJCO are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in oncology. Scope: Art of Oncology, Biology of Neoplasia, Breast Cancer, Cancer Prevention and Control, Cancer-Related Complications, Diagnosis in Oncology, Gastrointestinal Cancer, Genetic Testing For Cancer, Gynecologic Cancer, Head and Neck Cancer, Hematologic Malignancy, Lung Cancer, Melanoma, Molecular Oncology, Neurooncology, Palliative and Supportive Care, Pediatric Oncology, Surgical Oncology, Translational Oncology, and Urologic Oncology.